Caris Life Sciences (CAI) Operating Expenses (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Operating Expenses of $210.9 million for Q1 2026, up 17.9% year-over-year from $178.9 million in Q1 2025, and up 3.14% quarter-over-quarter from $204.5 million in Q4 2025.
Caris Life Sciences (CAI) Operating Expenses (2024 - 2026) Analysis & Trends
Caris Life Sciences' Operating Expenses history runs 3 years deep, the most recent figure standing at $210.9 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 17.9% year-over-year to $210.9 million; the TTM figure through Mar 2026 stood at $798.9 million (up 18.3% YoY), while the FY2025 annual figure was $766.9 million, up 14.57% from the prior year.
- Operating Expenses for Q1 2026 stood at $210.9 million, up from $204.5 million in the prior quarter.
- The five-year high for Operating Expenses was $210.9 million in Q1 2026, with the low at $162.5 million in Q3 2024.
- The 3-year median for Operating Expenses is $181.5 million (2025), against an average of $184.3 million.
- Peak annual rise in Operating Expenses reached 22.47% in 2025, while the deepest fall reached 13.37% in 2025.
- Caris Life Sciences' Operating Expenses stood at $167.0 million in 2024, then climbed by 22.47% to $204.5 million in 2025, then grew by 3.14% to $210.9 million in 2026.
- Business Quant data shows CAI's Operating Expenses at $210.9 million in Q1 2026, $204.5 million in Q4 2025, and $184.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | 236.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 236.79 Mn |
| Mar 31, 2026 | 210.89 Mn |
| Dec 31, 2025 | 204.48 Mn |
| Sep 30, 2025 | 184.19 Mn |
| Jun 30, 2025 | 199.39 Mn |
| Mar 31, 2025 | 178.87 Mn |
| Dec 31, 2024 | 166.96 Mn |
| Sep 30, 2024 | 162.46 Mn |
| Jun 30, 2024 | 167.06 Mn |